Fig. 1)

Biochemical progression-free survival (bPFS; 1a) and freedom from biochemical failure (FFBF; 1b) after whole-pelvic radiotherapy (WPRT) compared to fossa-only radiotherapy (PBRT) in patients with locally advanced node-negative prostate carcinomas after prostatectomy. Albeit not significantly different, the PBRT group included a higher percentage of patients with salvage indication (53.2%) compared to the WPRT group (39.5%); furthermore, patients were treated earlier after surgery in the WPRT group (6.1 months vs. 13.3 months, p = 0.003) likely confounding these results in favor of WPRT. Other baseline imbalances are shown in Table 1. a Mean bPFS in the WPRT group was 66.4 months (95%-CI: 53.6–79.2 months; median: 67.6 months) and significantly longer (p = 0.032) compared to 44.7 months (95%-CI: 35.4–54.0 months; median: 28.7 months) in the PBRT group. b Mean FFBF in the WPRT group was 67.9 months (95%-CI: 55.1–80.7 months; median: 67.6 months) and significantly increased (p = 0.033) compared to 46.1 months (95%-CI: 36.7–55.5 months; median: 31.5 months) in the PBRT group